The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of cetuximab (cet) and mFOLFOX6 in metastatic colorectal cancer (mCRC) (JACCRO CC-05).
Tatsuro Yamaguchi
No relevant relationships to disclose
Akihito Tsuji
Honoraria - Bristol-Myers Squibb; Merck; Yakult
Yu Sunakawa
No relevant relationships to disclose
Masato Nakamura
Honoraria - Bristol-Myers Squibb; Yakult
Mitsugu Kochi
Honoraria - Yakult
Tadamichi Denda
No relevant relationships to disclose
Ken Shimada
No relevant relationships to disclose
Satoshi Tani
No relevant relationships to disclose
Akinori Takagane
No relevant relationships to disclose
Masahito Kotaka
Honoraria - Bristol-Myers Squibb; Merck; Yakult
Hidekazu Kuramochi
No relevant relationships to disclose
Junichi Koike
No relevant relationships to disclose
Kaoru Furushima
No relevant relationships to disclose
Yutaka Yonemura
No relevant relationships to disclose
Yuji Negoro
No relevant relationships to disclose
Yasutaka Takinishi
No relevant relationships to disclose
Masahiro Takeuchi
Consultant or Advisory Role - Merck
Wataru Ichikawa
Honoraria - Bristol-Myers Squibb; Merck
Masashi Fujii
No relevant relationships to disclose
Toshifusa Nakajima
No relevant relationships to disclose